



**SOLVE  
ON.**



**EMBARGOED UNTIL 31 August 2021 at 15:00 CET**

## **Incyte Announces the Opening of the Incyte BioPlant, a New Multi-product, High-efficiency Manufacturing Facility in Yverdon-les-Bains**

**Yverdon-les-Bains, Switzerland – 31 August 2021** – Incyte, a U.S.-based global biopharmaceutical company focused on the discovery, development and commercialization of novel medicines, today announced the opening of the Incyte BioPlant in Y-PARC, Switzerland’s largest technology park located in Yverdon-les-Bains.

This new multi-product, high-efficiency, facility consists of a 13,300 square meter campus composed of three buildings housing production, technical operations and analytical labs. At full capacity, the Incyte BioPlant can house approximately 130 employees with expertise in manufacturing, quality control, process development, process engineering, plant engineering, maintenance, quality assurance and supply chain.

“We are proud to officially open our new BioPlant and begin production of important, potentially life-saving, medicines for patients with cancer,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “We believe this new facility exemplifies our commitment to driving collaborative innovation, and we want to thank our partners, including the City of Yverdon, Canton du Vaud and Y-PARC, for their support and cooperation throughout this project.”

“The opening of the Incyte Bioplant site reinforces the numerous expertise and skills in the field of biomanufacturing that already exist in Canton of Vaud. It contributes to the creation of jobs with very high added value in the heart of the Health Valley and thus further establishes the Canton of Vaud as a major innovation hub in the field of life sciences. The Government of the State of Vaud thanks the management team of Incyte for the significant investment made on the Y-PARC technology park,” said Philippe Leuba, State Councilor, Head of Department of Economic Affairs, Innovation and Sport, Canton Vaud.

The BioPlant can manufacture biologically active pharmaceutical ingredients (API) for commercial and clinical use. It also includes laboratory space for process development and optimization, and will be focused on producing oncology products, specifically monoclonal antibodies (mAbs).

Pierre Dessemontet, Mayor of Yverdon-les-Bains, added, “The City of Yverdon-les-Bains is proud to welcome such a key player in the biopharmaceutic industry to Y-PARC. The opening of Incyte’s new facility is yet another example of our city and our region’s economic vitality and growth over the recent years. In addition to leading cutting-edge research and development in the field of oncology, Incyte’s new BioPlant

will also allow for the creation of additional employment opportunities in Yverdon-les-Bains.”

“Y-PARC is proud and honored to count the Incyte BioPlant among 200 other innovative companies located on the park. Y-PARC’s DNA is to offer an appropriate environment to favor companies’ future development and a stimulating ecosystem with local high-tech competence. We are looking forward to collaborating and writing a new chapter in our collaboration with Incyte,” said Olivier Collet, Interim Director of Y-PARC.

Incyte is pursuing site qualifications for the Bioplant via Swissmedic/European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

### **About Incyte**

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [Incyte.com](https://www.incyte.com) and follow [@Incyte](https://twitter.com/Incyte).

### **Forward-looking Statements**

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s production facilities in Y-PARC and its plans to hire employees there, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2021. Incyte disclaims any intent or obligation to update these forward-looking statements.

# # #

### **Notes to editor:**

Incyte’s consolidated European headquarters in Morges – named Campus Leman – was inaugurated in July 2020 is home to more than 150 Incyte employees from the Company’s clinical development, technical operations, commercial and support teams.

### **Contacts:**

Catalina Loveman  
Tel: +1 302 498 6171  
Email: [cloveman@incyte.com](mailto:cloveman@incyte.com)

David Folley  
Tel: +41 (0) 22 552 46 21  
Email: [folley@cpc-pr.com](mailto:folley@cpc-pr.com)